share_log

JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200

Benzinga ·  May 3 00:45

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 to $200.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment